The survival and immune reprogramming data may reframe clinical development strategy around sequencing and durability rather than response rate. Traders should monitor for upcoming trial expansions, partnership announcements, or FDA guidance on trial design for accelerated approval pathways.
Price Chart
Executive Summary
MiNK Therapeutics announced positive Phase II trial data for its agenT-797 cell therapy in combination with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer, showing a 77% disease control rate and improved survival with an induction strategy. Despite missing the primary endpoint of ORR, the durable responses and immune activation support further development. The data are being presented at AACR 2026.
Key Facts
- Phase II trial (n=17) showed 77% disease control rate (DCR) in PD-1 refractory gastroesophageal cancer patients.
- Induction strategy with agenT-797 led to median PFS of 6.9 months vs. 3.5 months (HR 0.19; p=0.015) and median OS of 9.5 vs. 5.2 months.
- 43% of induction-treated patients were alive at 12 and 18 months, compared to 20% and 0% in non-induction cohort.
- Trial did not meet primary endpoint of ORR, but durable disease control and survival are emphasized as key benefits.
- Biomarker analyses show immune activation, T-cell infiltration, and tertiary lymphoid structure formation.
Financial Impact
High clinical significance despite small sample size; potential to accelerate development and attract partnerships.
Risk Factors
- Small trial size (n=17) limits statistical power and generalizability.
- Primary endpoint (ORR) not met, which may raise skepticism among some investors.
- Safety profile includes immune-related adverse events such as colitis and hepatitis.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276455 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access